文献速递白血病

IRF8被鉴定为小鼠急性早幼粒细胞白血病中的强效抑癌因子

Identification of IRF8 as a potent tumor suppressor in murine acute promyelocytic leukemia.
PubMed 文献 · Blood Adv · 2018-01-01

研究在小鼠MRP8-PML/RARA急性早幼粒细胞白血病(APL)模型中分析转录组,发现PML/RARA表达伴早幼粒细胞区室扩增及Irf8 mRNA下调。纯化早幼粒细胞中IRF8蛋白显著降低,IRF8缺失可致早幼粒细胞体内扩增并部分模拟PML/RARA表型,完全缺失IRF8加速APL发生。

要点

  • PML/RARA转基因小鼠早幼粒细胞中Irf8 mRNA和IRF8蛋白水平显著下调。
  • IRF8缺失导致体内早幼粒细胞扩增,部分模拟PML/RARA表达的影响。
  • 完全缺失IRF8可加速PML/RARA小鼠APL的发生。

核心结论

  • IRF8下调是APL起始的重要因子,IRF8在该急性白血病中发挥抑癌作用。

研究设计与样本

  • 研究采用小鼠MRP8-PML/RARA APL模型进行转录组分析、蛋白检测及生存实验。

主要发现

  • PML/RARA转基因小鼠高度纯化的早幼粒细胞群体中IRF8蛋白水平显著下调。
  • IRF8缺失导致体内早幼粒细胞扩增,部分模拟PML/RARA表达的影响。
  • 生存实验显示完全缺失IRF8导致PML/RARA小鼠APL发生加速。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although the role of promyelocytic leukemia/retinoic acid receptor α (PML/RARA) fusion protein is well recognized in acute promyelocytic leukemia (APL), its contribution to initiation and maintenance of leukemogenesis is not completely understood. Transcriptome analysis in the murine MRP8-PML/RARA APL model has demonstrated modest alterations in gene expression accompanied by expansion of the promyelocyte compartment. Of particular interest, mice expressing PML/RARA showed downregulation of the transcription factor Irf8 mRNA. Interferon regulatory factor 8 (IRF8) is a known regulator of hematopoiesis. Previous research had implicated IRF8 as a tumor suppressor for myeloid neoplasia, and mice lacking IRF8 develop a well-differentiated myeloproliferative neoplasm characterized by expansion of neutrophilic lineage cells. We hypothesized that PML/RARA-mediated downregulation of Irf8 transcript levels contributes to the initiation of APL. We observed significant downregulation of IRF8 protein levels in highly purified promyelocyte populations of PML/RARA transgenic mice. We also found that loss of IRF8 results in expansion of promyelocytes in vivo, partially phenocopying the impact of PML/RARA expression. Moreover, survival experiments showed that complete loss of IRF8 leads to acceleration of APL onset in our PML/RARA mice. Collectively, these data identify IRF8 downregulation as an important factor in APL initiation and highlight a tumor-suppressor role for IRF8 in this acute leukemia.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Gaillard C, Surianarayanan S, Bentley T, et al. Identification of IRF8 as a potent tumor suppressor in murine acute promyelocytic leukemia. Blood Adv. 2018. PMID: 30266821. doi:10.1182/bloodadvances.2018018929

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。